{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:40:19Z","timestamp":1772034019397,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.canlet.2025.217455","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:33:01Z","timestamp":1736537581000},"page":"217455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR\/ALK-TKIs"],"prefix":"10.1016","volume":"612","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-8723","authenticated-orcid":false,"given":"Xinjun","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weina","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wencui","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217455_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217455_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217455_bib3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217455_bib4","article-title":"RET rearrangements in non-small cell lung cancer: evolving treatment landscape and future challenges","volume":"1877","author":"Servetto","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2025.217455_bib5","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1158\/1078-0432.CCR-18-4049","article-title":"Analysis of cell-free DNA from 32,989 advanced cancers reveals novel Co-occurring activating RET alterations and oncogenic signaling pathway aberrations","volume":"25","author":"Rich","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217455_bib6","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/cncr.34451","article-title":"Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X\/L861Q\/S768I","volume":"128","author":"Pang","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217455_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2021.01.052","article-title":"Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer","volume":"148","author":"Lee","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217455_bib8","first-page":"4169","article-title":"Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma","volume":"19","author":"Yamaura","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2025.217455_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-022-00915-9","article-title":"Histomolecular resistance mechanisms to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer: a multicentric retrospective French study","volume":"17","author":"Akli","year":"2022","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2025.217455_bib10","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217455_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217455_bib12","article-title":"Durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ANK3-RET fusion in EGFR-mutated non-small-cell lung cancer","volume":"6","author":"Urbanska","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2025.217455_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217455_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.annonc.2022.01.004","article-title":"Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients","volume":"33","author":"Chen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217455_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/PO.21.00083","article-title":"Divergent RET- and BRAF-mediated resistance to osimertinib in EGFR-mutant NSCLC: a case report","volume":"5","author":"Rehman","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2025.217455_bib16","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","article-title":"Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217455_bib17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12967-022-03593-3","article-title":"RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"20","author":"Wang","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217455_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.trecan.2019.09.008","article-title":"Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer","volume":"5","author":"Zhu","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2025.217455_bib19","article-title":"Durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ANK3-RET fusion in EGFR-mutated non-small-cell lung cancer","volume":"6","author":"Urbanska","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2025.217455_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.644472","article-title":"The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy","volume":"11","author":"Friedlaender","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217455_bib21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.21037\/tlcr-20-1125","article-title":"Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib","volume":"10","author":"Ding","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.217455_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3727\/096504018X15344979253618","article-title":"Clinical characteristics and molecular patterns of RET-rearranged lung cancer in Chinese patients","volume":"27","author":"Zhang","year":"2019","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2025.217455_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.21037\/tlcr-22-202","article-title":"Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients","volume":"11","author":"Feng","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.217455_bib24","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.2147\/CMAR.S197337","article-title":"Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors","volume":"11","author":"Xu","year":"2019","journal-title":"Cancer Manag. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:57:19Z","timestamp":1760741839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"alternative-id":["S0304383525000199"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217455","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR\/ALK-TKIs","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217455"}}